Hepatic transit times and liver elasticity compared with meld in predicting a 1 year adverse clinical outcome of a clinically diagnosed cirrhosis

Česká verzia

Authors: Tomáš Koller ¹; Zuzana Piešťanská ¹; Tibor Hlavatý ¹; Jozef Holomáň ²; Jozef Glasa ²; Juraj Payer ¹
Authors place of work: V. interná klinika LF UK a UN Bratislava – Nemocnica Ružinov, Slovenská republika ¹; Ústav farmakológie, klinickej a experimentálnej farmakológie SZU Bratislava, Slovenská republika ²
Published in the journal: Vnitř Lék 2016; 62(5): 351-359
Category: Původní práce

Summary

Introduction and objectives:
Hepatic transit times measured by the contrast enhanced ultrasonography and liver elasticity were found to predict a clinically significant portal hypertension. However, these modalities we not yet sufficiently evaluated in predicting adverse clinical outcome in patients with clinically diagnosed cirrhosis (D´Amico stages > 1), having a clinically significant portal hypertension. The aim of our study was to assess the predictive power of the liver transit times and the liver elasticity on an adverse clinical outcome of clinically diagnosed cirrhosis compared with the MELD score.

Methods:
The study group included 48 consecutive outpatients with cirrhosis in the 2., 3. and 4. D’Amico stages. Patients with stage 4 could have jaundice, patients with other complications of portal hypertension were excluded. Transit times were measured from the time of intravenous administration of contrast agent (Sonovue) to a signal appearance in a hepatic vein (hepatic vein arrival time, HVAT) or time difference between the contrast signal in the hepatic artery and hepatic vein (hepatic transit time, HTT) in seconds. Elasticity was measured using the transient elastography (Fibroscan). The transit times and elasticity were measured at baseline and patients were followed for up for 1 year. Adverse outcome of cirrhosis was defined as the appearance of clinically apparent ascites and/or hospitalization for liver disease and/or death within 1 year.

Results:
The mean age was 61 years, with female/male ratio 23/25. At baseline, the median Child-Pugh score was 5 (IQR 5.0–6.0), MELD 9.5 (IQR 7.6 to 12.1), median HVAT was 22 s (IQR 19–25) and HTT 6 (IQR 5–9). HTT and HVAT negatively correlated with Child-Pugh (-0.351 and -0.441, p = 0.002) and MELD (-0.479 and -0.388, p = 0.006) scores. The adverse outcome at 1-year was observed in 11 cases (22.9 %), including 6 deaths and 5 hospitalizations. Median HVAT in those with/without the adverse outcome was 20 seconds (IQR 19.3–23.5) compared with 22 s (IQR 19–26, p = 0.32). Cases with adverse outcome had significantly higher MELD (12.9 vs 8.5), Child-Pugh score (7.0 vs 5.0) and the liver elasticity (52.5 vs 21.5 kPa) (p < 0.05). The AUROC of the HVAT, liver elasticity and MELD for the prediction of the adverse outcome was 0.60 (95% CI 0.414 to 0.785), 0.767 (0.56 to 0.98) and 0.813 (0.66 to 0.97). Unlike HVAT, the liver elasticity > 35.3 kPa increased the risk of the adverse outcome 10.3-times and MELD score > 11 points 8.5-times.

Conclusion:
In patients with clinically diagnosed cirrhosis having a clinically significant portal hypertension hepatic transit times do not predict the 1-year adverse clinical outcome. However, the liver elasticity > 35.3 kPa appears clinically useful with a prognostic value comparable with MELD.

Key words:
clinically diagnosed cirrhosis – hepatic transit times – liver elasticity – MELD – portal hypertension

Zdroje

1. Mokdad A, Lopez AD, Shahraz S et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med 2014; 12: 145. Dostupné z DOI: <http://dx.doi.org/10.1186/s12916–014–0145-y>.

2. Blachier M, Leleu H, Peck-Radosavljevic M et al. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013; 58(3): 593–608.

3. Zpráva o zdraví obyvatel České republiky (2014). Ministerstvo zdravotnictví České republiky. Dostupné z WWW: <http://www.mzcr.cz/verejne/dokumenty/zprava-o-zdravi-obyvatel-ceske-republiky2014-_9420_3016_5.html>.

4. Maniecka-Bryła I, Bryła M, Bryła P et al. The burden of premature mortality in Poland analysed with the use of standard expected years of life lost. BMC Public Health 2015; 15: 101. Dostupné z DOI: <http://dx.doi.org/10.1186/s12889–015–1487-x>.

5. D´Amico G. Natural History and Stages of Cirrhosis. In: De Franchis R, Dell´Era A (eds.) Variceal Hemorrhage. Springer Science + Bussiness Media: New York 2014: 203–210. ISBN 978–1493900015.

6. Jepsen P, Ott P, Andersen PK et al. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology 2010; 51(5): 1675–1682.

7. Kitson MT, Roberts SK, Colman JC et al. Liver stiffness and the prediction of clinically significant portal hypertension and portal hypertensive complications. Scand J Gastroenterol 2015; 50(4): 462–469.

8. Kim MY, Suk KT, Baik SK et al. Hepatic Vein Arrival Time as Assessed by Contrast-Enhanced Ultrasonography Is Useful for the Assessment of Portal Hypertension in Compensated Cirrhosis. Hepatology 2012; 56(3): 1053–1062.

9. Berzigotti A, Reverter E, Garcia-Criado A et al. Reliability of the estimation of total hepatic blood flow by Doppler ultrasound in patients with cirrhotic portal hypertension. J Hepatol 2013; 59(4): 717–722.

10. Koller T, Kindlová J, Šturdík I et al. Prognostické indexy cirhózy a ich vzťah k prirodzenému priebehu a k príčinám úmrtia pacientov s cirhózou v slovenskej populácii pred érou transplantácie pečene. Trendy v hepatológii 2013; 5(1): 26.

11. Marcellin P, Gane E, Buti M et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381(9865): 468–475.

12. von Herbay A, Vogt C, Willers R et al. Real-time imaging with the sonographic contrast agent SonoVue: differentiation between benign and malignant hepatic lesions. J Ultrasound Med 2004; 23(12): 1557–1568.

13. Lim KP, Taylor-Robinson SD, Patel N et al. Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut 2005; 54(1): 128–133.

14. Sugimoto H, Kaneko T, Hirota M et al. Earlier hepatic vein transit-time measured by contrast ultrasonography reflects intrahepatic hemodynamic changes accompanying cirrhosis. J Hepatol 2002; 37(5): 578–583.

15. Pedersen JF, Larsen V, Bytzer P et al. Hepatic transit time of ultrasound contrast in biopsy characterized liver disease. Acta Radiol 2005; 46(6): 557–560.

16. Li N, Ding H, Fan P et al. Intrahepatic transit time predicts liver fibrosis in patients with chronic hepatitis B: quantitative assessment with contrast-enhanced ultrasonography. Ultrasound Med Biol 2010; 36(7): 1066–1075.

17. Liu GJ, Lu MD. Diagnosis of liver cirrhosis with contrast-enhanced ultrasound. World J Radiol 2010; 2(1): 32–36.

18. Zhang CX, Hu J, Hu KW et al. Noninvasive analysis of portal pressure by contrast-enhanced sonography in patients with cirrhosis. J Ultrasound Med 2011; 30(2): 205–211.

19. Amat-Roldan I, Berzigotti A, Gilabert R et al. Assessment of Hepatic Vascular Network Connectivity with Automated Graph Analysis of Dynamic Contrast-enhanced US to Evaluate Portal Hypertension in Patients with Cirrhosis: A Pilot Study. Radiology 2015, 277(1): 268–276.Dostupné z DOI: <http://dx.doi.org/10.1148/radiol.2015141941>.

20. Hong WK, Kim MY, Baik SK et al. The usefulness of non-invasive liver stiffness measurements in predicting clinically significant portal hypertension in cirrhotic patients: Korean data. Clin Mol Hepatol 2013; 19(4): 370–375.

21. Kuo YH, Lu SN, Hung CH et al. Liver stiffness measurement in the risk assessment of hepatocellular carcinoma for patients with chronic hepatitis. Hepatol Int 2010; 4(4): 700–706.

22. Robic MA, Procopet B, Metivier S et al. Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study. J Hepatol 2011; 55(5): 1017–1024.

23. Reiberger T, Ferlitsch A, Payer BA et al. Noninvasive screening for liver fibrosis and portal hypertension by transient elastography – a large single center experience. Wien Klin Wochenschr 2012; 124(11–12): 395–402.

24. Kim SU, Lee JH, Kim DY et al. Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis. PLoS One 2012; 7(5): e36676. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0036676>.

25. Singh S, Fujii LL, Murad MH et al. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013; 11(12): 1573 -1584.e1–2; quiz e88–9. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cgh.2013.07.034>.

26. Hall A, Germani G, Isgro G et al. Fibrosis distribution in explanted cirrhotic livers. Histopathology 2012; 60(2): 270–277.

27. Singal AK, Kamath PS. Model for End-stage Liver Disease. J Clin Exp Hepatol 2013; 3(1): 50–60.

28. Fejfar T, Safka V, Hulek P et al. MELD score in prediction of early mortality in patients suffering refractory ascites treated by TIPS. Vnitř Lék 2006; 52(9): 771–776.

29. Louvet A, Labreuche J, Artru F et al. Combining Data From Liver Disease Scoring Systems Better Predicts Outcomes of Patients With Alcoholic Hepatitis. Gastroenterology 2015; 149(2): 398–406.e8; quiz e16–7. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2015.04.044>.

30. Kraja B, Sina M, Mone I et al. Predictive Value of the Model of End-Stage Liver Disease in Cirrhotic Patients with and without Spontaneous Bacterial Peritonitis. Gastroenterol Res Pract 2012; 2012: 539059. Dostupné z DOI: <http://dx.doi.org/10.1155/2012/539059>.

31. Alessandria C, Ozdogan O, Guevara M et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2005; 41(6): 1282–1289.

32. Ripoll C, Groszmann R, Garcia-Tsao G et al. Hepatic Venous Pressure Gradient Predicts Clinical Decompensation in Patients With Compensated Cirrhosis. Gastroenterology 2007; 133(2): 481–488.

33. Umemura T, Shibata S, Sekiguchi T et al. Serum sodium concentration is associated with increased risk of mortality in patients with compensated liver cirrhosis. Hepatol Res 2015; 45(7): 739–744.

34. Sembera S, Jirkovsky V, Fejfar T et al. Survival of patients after TIPS in the University Hospital Hradec Kralove. Vnitř Lék 2011; 57(12): 1038–1044.